Skip to main content
Figure 2 | BMC Infectious Diseases

Figure 2

From: Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study

Figure 2

Longitudinal evaluation of candidate pro-inflammatory/anti-inflammatory cytokine and cytokine/receptor ratios categorized by incident neuropathic symptom status. Incident neuropathic symptoms developed within 12 weeks of starting cART. The control group refers to the symptom-free nested control group paired for previously identified risk factors. *refers to within-group differences from baseline, p < 0.05. # refers to between-group differences from baseline levels, p < 0.05. Horizontal bars indicate median values with interquartile ranges. Baseline refers to pre-cART levels. Abbreviations: IL, interleukin; sIL, soluble interleukin; TNFα, tumour necrosis factor-α.

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us